All In Biotech

Drug Trial Radar · NCT05750589

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Pain and Corneal Epitheliopathy

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jan 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
iRenix Medical, Inc.Industry
Sponsor type
Industry
First posted
Mar 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.

Conditions

  • Retinal Disease

Interventions

  • IRX-101Drug

    IRX-101 is a novel ocular anti-septic

  • Providone-IodineDrug

    5% Providone-Iodine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of post-intravitreal injection eye painTime frame: Demonstrate a reduction in mean 1-hr post-injection pain scores

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • R. Gary Lane, II MD

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.